Comparative Pharmacology
Head-to-head clinical analysis: CARDENE versus TRIVARIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARDENE versus TRIVARIS.
CARDENE vs TRIVARIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cardene (nicardipine) is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle. It dilates peripheral arterioles, reducing systemic vascular resistance and blood pressure, and also has coronary vasodilatory effects.
TRIVARIS combines an opioid agonist-antagonist (buprenorphine) and a mu-opioid receptor antagonist (naloxone). Buprenorphine partially binds to mu-opioid receptors, reducing withdrawal and craving, while naloxone precipitates withdrawal if injected, deterring abuse.
20-40 mg orally three times daily.
TRIVARIS 10 mg orally once daily, with or without food.
None Documented
None Documented
1.5-2 hours (terminal); prolonged in hepatic impairment (up to 6-8 hours)
Terminal half-life 12-18 hours; allows twice-daily dosing in chronic therapy
Renal: 60% as metabolites, 10% unchanged; Fecal: 35%
Renal: 60% unchanged; Biliary/Fecal: 30% as metabolites; 10% minor pathways
Category C
Category C
Calcium Channel Blocker
Angiotensin II Receptor Blocker + Calcium Channel Blocker + Thiazide Diuretic Combination